ASCO 2022 | Expression of CD47 and CALR in MPNs
Increases of both CALR and CD47 on the cell membrane have been observed in response to chemotherapy, however, their role in myeloid malignancies is poorly understood. Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the results of a study investigating the expression and cellular localization of CALR and CD47 in untreated and treated patients with essential thrombocythemia (ET), polycythemia vera (PV) myelofibrosis (MF), in comparison with healthy controls. A significant difference was observed in CD47 expression across different myeloproliferative neoplasm (MPN) subtypes with a significant increase in CD47 expression in PV and MF but not ET. Therefore the use of anti-CD47 antibodies could represent a new strategy to enhance the treatment response in particular in PV and MF. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
